Nurix CLO sells 8,148 shares under 10b5-1 plan
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring sold 8,148 shares of common stock in an open-market transaction on March 2, 2026. The shares were sold at a weighted average price of $15.4385 per share under a previously adopted Rule 10b5-1 trading plan. Following this sale, she directly holds 34,601 Nurix shares.
Insider Trade Summary
Net Seller: 8,148 shares
Net Sell
1 txn
Insider
Ring Christine
Role
Chief Legal Officer
Sold
8,148 shs ($126K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 8,148 | $15.4385 | $126K |
Holdings After Transaction:
Common Stock — 34,601 shares (Direct)
Footnotes (2)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- F2. Represents the weighted average sale price. The lowest price at which shares were sold was $15.16 and the highest price at which shares were sold was $15.845. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
AI-generated analysis. How Rhea-AI works. Not financial advice.